Morgan Stanley Call 230 PGR 20.09.../ DE000ME7UHW1 /
31/07/2024 13:59:36 | Chg.-0.030 | Bid17:14:15 | Ask17:14:15 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.440EUR | -6.38% | 0.420 Bid Size: 40,000 |
0.440 Ask Size: 40,000 |
Progressive Corporat... | 230.00 USD | 20/09/2024 | Call |
GlobeNewswire
25/06
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
24/06
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Tri...
GlobeNewswire
24/06
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geo...
GlobeNewswire
24/06
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-4...
GlobeNewswire
13/06
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Progr...
GlobeNewswire
12/06
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo...
GlobeNewswire
12/06
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japa...
GlobeNewswire
11/06
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
11/06
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b...
GlobeNewswire
11/06
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclero...
GlobeNewswire
10/06
LifeWallet’s Proprietary Data System is Instrumental in Class Certification Against USAA Property an...